Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Roluperidone - Minerva Neurosciences/Tanabe Pharma Corporation

Next Previous
Drug Profile

Roluperidone - Minerva Neurosciences/Tanabe Pharma Corporation

Alternative Names: CYR-101; MIN-101; MT-210

Latest Information Update: 14 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Mitsubishi Tanabe Pharma Corporation
  • Developer Minerva Neurosciences
  • Class Antidementias; Antiparkinsonians; Antipsychotics; Behavioural disorder therapies; Fluorobenzenes; Isoindoles; Piperidines; Small molecules
  • Mechanism of Action Alpha-1a adrenergic receptor antagonists; Serotonin 5-HT2A receptor antagonists; Sigma-2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Schizophrenia
  • No development reported Alzheimer's disease; Autism spectrum disorder; Dementia; Parkinson's disease

Most Recent Events

  • 01 Apr 2026 Minerva Neurosciences plans a confirmatory phase III trial for Schizophrenia in USA, Europe(PO) in the second quarter of 2026
  • 01 Dec 2025 Mitsubishi Tanabe Pharma Corporation is now called Tanabe Pharma Corporation
  • 22 Oct 2025 Minerva Neurosciences prepares for commercial launch of Roluperidone in the US

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top